CENTRAL TRUST Co Has $48.58 Million Stock Holdings in AbbVie Inc. $ABBV

CENTRAL TRUST Co lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 1.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 212,594 shares of the company’s stock after selling 3,755 shares during the quarter. AbbVie accounts for approximately 1.0% of CENTRAL TRUST Co’s investment portfolio, making the stock its 26th biggest position. CENTRAL TRUST Co’s holdings in AbbVie were worth $48,576,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Centennial Wealth Advisory LLC boosted its holdings in shares of AbbVie by 2.2% in the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after purchasing an additional 45 shares in the last quarter. Weil Company Inc. boosted its holdings in shares of AbbVie by 2.3% in the 3rd quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock valued at $469,000 after purchasing an additional 46 shares in the last quarter. Hardin Capital Partners LLC boosted its holdings in shares of AbbVie by 1.4% in the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after purchasing an additional 46 shares in the last quarter. Inlet Private Wealth LLC boosted its holdings in shares of AbbVie by 0.3% in the 3rd quarter. Inlet Private Wealth LLC now owns 17,001 shares of the company’s stock valued at $3,937,000 after purchasing an additional 47 shares in the last quarter. Finally, D.B. Root & Company LLC boosted its holdings in shares of AbbVie by 4.3% in the 3rd quarter. D.B. Root & Company LLC now owns 1,152 shares of the company’s stock valued at $267,000 after purchasing an additional 47 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $240.00 target price on shares of AbbVie in a report on Thursday. Evercore reduced their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Royal Bank Of Canada started coverage on AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. Guggenheim reissued a “buy” rating and set a $249.00 price objective on shares of AbbVie in a report on Friday. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $252.90.

AbbVie Stock Down 2.2%

NYSE ABBV opened at $206.63 on Friday. AbbVie Inc. has a twelve month low of $176.57 and a twelve month high of $244.81. The company has a market cap of $365.36 billion, a price-to-earnings ratio of 101.79, a price-to-earnings-growth ratio of 0.74 and a beta of 0.32. The business’s fifty day moving average is $214.55 and its 200 day moving average is $221.54.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter last year, the business posted $2.46 EPS. AbbVie’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, research analysts anticipate that AbbVie Inc. will post 14.29 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is 340.89%.

Insider Buying and Selling at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by company insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell?side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post?Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque?psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long?term commitment to immunology innovation, but limited near?term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near?term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.